C Solas (1), MC Gagnieu (2), I Ravaux (3), MP Drogoul (4), A Lafeuillade (5), S Mokhtari (6), B Lacarelle (1) and N Simon (1).
Population Pharmacokinetics of Atazanavir in HIV-infected Patients
|
C.M.T. Sherwin (1, 2), N.J. Medlicott (2), R. Broadbent (1), D.M. Reith (1).
Simulation and development of a netilmicin extended dosing regimen for extremely premature neonates.
|
Zhao W (1), Baudouin V (2), Zhang D (1) and Jacqz-Aigrain E (1)
Population Pharmacokinetics of Ganciclovir Following Oral Administration of its Prodrug Valganciclovir in Pediatric Renal Transplant Patients
|
M. Frank (1), A. Kunz (2), G. Harms (2), C. Kloft (1)
Nevirapine - Population pharmacokinetic model building and simulation for mothers and newborns
|
F.T. Musuamba(1), I. Delattre(1), P.F. Laterre(3), J. Cumps(4), F. Jacobs(5), R.K. Verbeeck(2 )and P. Wallemacq(1)
Simultaneous Therapeutic Drug Monitoring Of Amikacin And Beta-Lactams In Intensive Care Unit Patients With Severe Sepsis Or Septic Shock Without Beta-Lactam Serum Concentration Monitoring
|
S. Goutelle (1,2,3), L. Bourguignon (1,2), P.H. Maire (1,2), M. Van Guilder (3), R.W. Jelliffe (3), J. E. Conte Jr (4)
A Population Pharmacokinetic Study of Plasma and Intrapulmonary Concentrations of Rifampin
|
S. Goutelle (1,2,3), L. Bourguignon (1,2), P.H. Maire (1,2), M. Van Guilder (3), R.W. Jelliffe (3), J.E. Conte Jr (4,5)
Influence of Rifampin Pharmacokinetic Variability on Antibacterial Effect and Prevention of Resistance in Pulmonary Tuberculosis: a Simulation Study
|
Elisabet I Nielsen (1,2), Marie Sandström (1,3), Per Hartvig (2,4), Uwe Ewald (5), Lena E Friberg (1)
Developmental Pharmacokinetics of Gentamicin in Preterm and Term Neonates: Modelling and Simulation Based on Data from a Prospective Study
|
Jackson K. Mukonzo (1), Paul Waako (1), Daniel Röshammar (3), Maria Andersson (2), Jan-Olov Svensson (2), Jasper Ogwal-Okeng (1), Lars L Gustafsson (2), Eleni Aklillu (2)
Population Pharmacokinetics of Efavirenz and MDR-1, CY2B6, and CYP3A5 Polymorphisms
|
Dubois A (1), Duval X (1,2), Peytavin G (2), Taburet AM (3), Goujard C (3), Mentré F (1,2) and the Cophar1-ANRS 102 Trial Group
Population analysis of plasma and intracellular pharmacokinetics of indinavir in HIV-1 infected patients with a stable antiretroviral therapy
|
M. Neely (1), J. van den Anker (2), S. Soldin (2), K. Williams (2), A. Baghdassarian (2), N. Rakhmanina (2)
Population Kinetics and Dynamics of Lopinavir in HIV-Infected Children
|
C. Bazzoli (1), S. Retout (1, 2), E. Rey (3), H. Benech (4), J.M. Tréluyer (3), D. Salmon (5), X. Duval (1, 6, 7), F. Mentré (1, 2) and the COPHAR2- ANRS 111 study group
Population pharmacokinetics of AZT and its active metabolite AZT-TP in HIV patients: joint modelling and design optimisation
|
Caldes A2 , Colom H1 , Garrido MJ3, Trocóniz I3, Gilvernet S2, Armendariz Y2, Cendrós JM1, Peraire C1 , Grinyó JM2
Population pharmacokinetics of Ganciclovir following Valganciclovir in solid organ transplant recipients infected by cytomegalovirus
|
Jan-Stefan van der Walt (1), Phumla Sinxadi (1), Karen Cohen (1), Helen McIlleron (1), Gary Maartens (1). Mats O Karlsson (2)
Population pharmacokinetic models for lamivudine and nevirapine to assess drug concentrations obtained during therapeutic drug monitoring
|
R. McGready (1,2,3), J. Tarning (2), N. Lindegardh (2,3), E.A. Ashley (1,2,3), M. Pimanpanarak (1), B. Kamanikom (2), A. Annerberg (2), P. Singhasivanon (2), N.J. White (2,3), F. Nosten (1,2,3)
Population pharmacokinetics of lumefantrine in pregnant women treated with co-artemether for uncomplicated falciparum malaria
|
H Kimko, B Murthy, RS Strauss, S Xu, P Bagchi, P Nandy, K Bush, GJ Noel
Relationship Between a PK/PD Parameter and Therapeutic Response of Ceftobiprole in Patients with Complicate Skin and Skin Structure Infection
|
García MJ, Santos Buelga D, Cabrera S, Fernandez de Gatta MM, Domínguez-Gil
Population Pharmacokinetics of Efavirenz in HIV-infected patients: Pharmacogenetic analysis
|
